ICER had previously said that a ‘fair’ price for Relyvrio would be between $9,100 and $30,000 per year. Currently, the ALS drug is priced about five times higher than the top of a value-based ...

Meanwhile, Relyvrio has already been conditionally approved in Canada under the Albrioza brand name, although it has not yet launched there, as Amylyx remains in pricing negotiations.

Amylyx stock crashed Friday, losing almost all of its value, after the company said its approved ALS treatment, Relyvrio, failed in a pivotal study. Please watch the video at Investors.com - How ...